Skip to main content
OCUL logo

OCUL · Ocular Therapeutix, Inc · Investor Relations

Track OCUL — free
$5.99 +0.05 (+0.76%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.31B
Shares
220.02M
Volume · Nov 19 220.23K Avg daily vol (3M) 3.04M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-09 Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights

AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on submission package under 505(b)(2) pathway SOL-1 post-hoc analyses presented at AAO

2026-11-06 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired

2026-11-02 Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET

2026-10-29 Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.

2026-10-09 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired

2026-10-01 Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.

2026-09-18 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired

2026-09-15 Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that

2026-09-01 Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October

2026-08-13 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms.

2026-08-07 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired

2026-08-03 Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

Ocular’s AXPAXLI TM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient to Support Submission of AXPAXLI NDA in wet AMD AXPAXLI NDA submission to be

2026-07-09 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive

2026-07-01 Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.

2026-06-22 Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms.

Past events

Date Event Type
2026-11-17 UBS Global Biopharma Conference 2026 Conference
2026-11-17 UBS Global Biopharma Conference Conference
2026-11-09 Q3 2026 Earnings Conference Call Earnings call
2026-11-09 Ocular Therapeutix, Inc Q3 FY2026 Earnings Call Earnings call
2026-11-07 OSN New York & OSN New York Retina 2026 Conference
2026-11-05 The Empire Forum Conference
2026-10-22 Piper Sandler Virtual Fireside Chat Event
2026-10-20 Chardan 10th Annual Healthcare Conference Conference
2026-09-15 Baird 2026 Global Healthcare Conference Conference
2026-08-18 Piper Sandler Virtual Fireside Chat Event
2026-07-22 HC Wainwright 6th Annual Ophthalmology Virtual Conference Conference
2026-07-09 Piper Sandler Virtual Ophthalmology Symposium Event
2026-06-17 Ocular Therapeutix In-Person and Virtual Investor Day Presentation
2026-05-28 Vanguards of Healthcare by Bloomberg Intelligence Event
2026-05-26 Stifel 2026 Virtual Ophthalmology Forum Event
2026-05-12 Bank of America Health Care Conference 2026 Conference
2026-05-05 Ocular Therapeutix, Inc. Q1 Financial Results Conference Call Earnings call
2026-04-27 HCW @ Home with Ocular Therapeutix Event
2026-04-13 Vit-Buckle Society: SOL-1 Presentation Recap with Piper Sandler Presentation

Source: https://investors.ocutx.com/events-presentations

Key facts CIK 1393434 CUSIP 67576A100 13F (30d) 269 filings 250 filers Visit website Investor relations